MI Visit the ASPET Website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Related articles in MI
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Counts, S. E.
Right arrow Articles by Mufson, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Counts, S. E.
Right arrow Articles by Mufson, E. J.
Molecular Interventions 3:137-156 (2003)
© 2003 American Society of Pharmacology and Experimental Therapeutics

Review

Galanin in Alzheimer Disease

Scott E. Counts1, Sylvia E. Perez1, Stephen D. Ginsberg2, Sonsoles de Lacalle3 and Elliott J. Mufson1

1 Department of Neurological Sciences, Rush-Presbyterian-St. Luke’s Medical Center, 2242 West Harrison Street, Chicago, IL 60612,
2 Center for Dementia Research, Nathan Kline Institute, Departments of Psychiatry and Physiology & Neuroscience, New York University School of Medicine, 140 Old Orangeburg Road, Orangeburg, NY 10962
3 Department of Biological Sciences, California State University, Los Angeles, 5151 State University Drive, Los Angeles, CA 90032


Galanin (GAL) and GAL receptors (GALR) are overexpressed in limbic brain regions associated with cognition in Alzheimer disease (AD). The functional consequences of this overexpression are unclear. Because GAL inhibits cholinergic transmission and restricts long-term potentiation in the hippocampus, GAL overexpression may exacerbate clinical features of AD. In contrast, GAL expression increases in response to neuronal injury, and galaninergic hyperinnervation prevents the decreased production of protein phosphatase 1 subtype mRNAs in cholinergic basal forebrain neurons in AD. Thus, GAL may also be neuroprotective for AD. Further elucidation of GAL activity in selectively vulnerable brain regions will help gauge the therapeutic potential of GALR ligands for the treatment of AD.


Related articles in MI:

Sites of interest on the World Wide Web—edited by David Siderovski

MI 2003 3: 171. [Full Text]  





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.